Bronchopulmonary Dysplasia Market Insights Epidemiology And Market Forecast

DelveInsight's 'Bronchopulmonary Dysplasia (BPD) - Market Insights, Epidemiology and Market Forecast-2028' report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of Bronchopulmonary Dysplasia in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of BPD from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.


Geography Covered

• The United States

• EU5 (Germany, France, Italy, Spain and the United Kingdom)

• Japan


Study Period: 2017-2028


Bronchopulmonary Dysplasia - Disease Understanding and Treatment Algorithm

The DelveInsight Bronchopulmonary Dysplasia market report gives the thorough understanding of BPD by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Bronchopulmonary Dysplasia in the US, Europe, and Japan.


Bronchopulmonary Dysplasia Epidemiology

The Bronchopulmonary Dysplasia epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed and treatable patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report is segmented by Preterm and Early Preterm cases, Total cases of Bronchopulmonary Dysplasia, and Severity-specific cases [Mild, Moderate and Severe] in the 7MM.

According to DelveInsight, the total prevalent cases of Bronchopulmonary Dysplasia was 64,468 in 2017 in 7MM. Among 7MM, estimates show higher population of Bronchopulmonary Dysplasia (BPD) in the United States, reaching to 14,243 cases in 2028.


Bronchopulmonary Dysplasia Drug Chapters

This segment of the Bronchopulmonary Dysplasia report encloses the detailed analysis of marketed drugs and late stage (Phase-III) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.


Bronchopulmonary Dysplasia Market Outlook

The Bronchopulmonary Dysplasia market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

Currently, the treatment of Bronchopulmonary Dysplasia is dependent on ventilation, oxygen supplementation and supportive interventions such as steroids, surfactants, bronchodilators, vitamin A, methylxanthines, diuretics, antibiotics etc. However, many therapies remain controversial due to unacceptable side effects and randomized controlled trial testing and long-term outcome follow-up analysis. The management of BPD and its related problems thus remains a major challenge. However, improved understanding of the complex pathogenesis of BPD has led to the development of novel pharmacologic interventions for its prevention and treatment. As per DelveInsight estimates, the market size of Bronchopulmonary Dysplasia was found to be USD 307.69 million in 2017. This market is further expected to grow during the forecasted period of 2019-2028 at a CAGR of XX% owing to the launch of upcoming therapies. Detailed chapters of the promising upcoming therapies including PNEUMOSTEM (Medipost), AEROSURF (Windtree Therapeutics), CG100 (Therabron Therapeutics), and SHP607 (Shire/ Takeda) are also provided in the report.


Bronchopulmonary Dysplasia Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.


Bronchopulmonary Dysplasia Report Insights

• Patient Population

• Therapeutic Approaches

• Pipeline Analysis

• Market Size and Trends

• Market Opportunities

• Impact of upcoming Therapies


Bronchopulmonary Dysplasia Report Key Strengths

• 10 Year Forecast

• 7MM Coverage

• Epidemiology Segmentation

• Drugs Uptake

• Highly Analyzed Market

• Key Cross Competition


Bronchopulmonary Dysplasia Report Assessment

• Current Treatment Practices

• Unmet Needs

• Detailed Pipeline Product Profiles

• Market Attractiveness

• Market Drivers and Barriers


Key Benefits

• This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving the Bronchopulmonary Dysplasia market

• Organize sales and marketing efforts by identifying the best opportunities for Bronchopulmonary Dysplasia market

• To understand the future market competition in the Bronchopulmonary Dysplasia market.

1. Key Insights

2. Bronchopulmonary Dysplasia (BPD): Market Overview at a Glance

2.1. Total Market Share (%) Distribution of Bronchopulmonary Dysplasia (BPD) in 2017

2.2. Total Market Share (%) Distribution of Bronchopulmonary Dysplasia (BPD) in 2028

3. Bronchopulmonary Dysplasia (BPD): Disease Background and Overview

3.1. Introduction

3.2. Risk Factors

3.3. Signs and symptoms

3.4. Pathophysiology

3.5. Biomarkers of BPD

3.6. Diagnosis

4. Epidemiology and Patient Population

4.1. Key Findings

4.2. Total Cases of Bronchopulmonary Dysplasia in 7MM

4.3. United States Epidemiology

4.3.1. Assumptions and Rationale

4.3.2. Preterm and Early Preterm Cases in the United States

4.3.3. Total cases of Bronchopulmonary Dysplasia in the US

4.3.4. Severity Specific Cases of Bronchopulmonary Dysplasia in the United States

4.4. EU5 Epidemiology

4.5. Germany Epidemiology

4.5.1. Preterm and Early Preterm Cases in Germany

4.5.2. Total cases of Bronchopulmonary Dysplasia in Germany

4.5.3. Severity Specific Cases of Bronchopulmonary Dysplasia in Germany

4.6. France Epidemiology

4.6.1. Total Preterm and Early Preterm Cases in France

4.6.2. Total cases of Bronchopulmonary Dysplasia in France

4.6.3. Severity Specific Cases of Bronchopulmonary Dysplasia in France

4.7. Italy Epidemiology

4.7.1. Total Preterm and Early Preterm Cases in Italy

4.7.2. Total cases of Bronchopulmonary Dysplasia in Italy

4.7.3. Severity Specific Cases of Bronchopulmonary Dysplasia in Italy

4.8. Spain Epidemiology

4.8.1. Total Preterm and Early Preterm Cases in Spain

4.8.2. Total cases of Bronchopulmonary Dysplasia in Spain

4.8.3. Severity Specific Cases of Bronchopulmonary Dysplasia in Spain

4.9. United Kingdom Epidemiology

4.9.1. Total Preterm and Early Preterm Cases in the UK

4.9.2. Total cases of Bronchopulmonary Dysplasia in the UK

4.9.3. Severity Specific Cases of Bronchopulmonary Dysplasia in the UK

4.10. Japan Epidemiology

4.10.1. Assumptions and Rationale

4.10.2. Total Preterm and Early Preterm Cases in Japan

4.10.3. Total cases of Bronchopulmonary Dysplasia in Japan

4.10.4. Severity Specific Cases of Bronchopulmonary Dysplasia in Japan

5. Treatment and Management of BPD

5.1. Bronchopulmonary Dysplasia: Evidence-Based Pharmacologic Therapies

5.2. Management of Bronchopulmonary Dysplasia - US Preventive Services Task Force

5.3. Guidelines for use of postnatal corticosteroids in preterm neonates have been endorsed by pediatric associations in North America and Europe

6. Unmet Needs

7. Emerging Therapies

7.1. Key Cross Competition

7.2. PNEUMOSTEM: Medipost

7.2.1. Product Description

7.2.2. Other Developmental Activities

7.2.3. Clinical Development

7.2.4. Safety and Efficacy

7.2.5. Product Profile

7.3. AEROSURF: Windtree Therapeutics

7.3.1. Drug Description

7.3.2. Other Developmental Activities

7.3.3. Clinical Development

7.3.4. Safety and Efficacy

7.3.5. Product Profile

7.4. CG100: Therabron Therapeutics

7.4.1. Drug Description

7.4.2. Other Developmental Activities

7.4.3. Clinical Development

7.4.4. Safety and Efficacy

7.4.5. Product Profile

7.5. SHP607: Shire/ Takeda

7.5.1. Drug Description

7.5.2. Other Developmental Activities

7.5.3. Clinical Development

7.5.4. Safety and Efficacy

7.5.5. Product Profile

8. Bronchopulmonary Dysplasia (BPD): 7MM Market Analysis

8.1. Key Findings

8.2. Market Size of Bronchopulmonary Dysplasia in 7MM

8.3. Market Size of Bronchopulmonary Dysplasia by Therapies in 7MM

8.4. United States: Market Outlook

8.4.1. United States Market Size

8.4.2. Total Market size of Bronchopulmonary Dysplasia

8.4.3. Market Size of Bronchopulmonary Dysplasia by Therapies in the US

8.5. EU-5 countries: Market Outlook

8.6. Germany Market Size

8.6.1. Total Market size of Bronchopulmonary Dysplasia

8.6.2. Market Size of Bronchopulmonary Dysplasia by Therapies in Germany

8.7. France Market Size

8.7.1. Total Market size of Bronchopulmonary Dysplasia

8.7.2. Market Size of Bronchopulmonary Dysplasia by Therapies in France

8.8. Italy Market Size

8.8.1. Total Market size of Bronchopulmonary Dysplasia

8.8.2. Market Size of Bronchopulmonary Dysplasia by Therapies in Italy

8.9. Spain Market Size

8.9.1. Total Market size of Bronchopulmonary Dysplasia

8.9.2. Market Size of Bronchopulmonary Dysplasia by Therapies in Spain

8.10. United Kingdom Market Size

8.10.1. Total Market size of Bronchopulmonary Dysplasia

8.10.2. Market Size of Bronchopulmonary Dysplasia by Therapies in the UK

8.11. Japan Market Outlook

8.11.1. Japan Market Size

8.11.2. Total Market size of Bronchopulmonary Dysplasia

8.11.3. Market Size of Bronchopulmonary Dysplasia by Therapies in Japan

9. Market Drivers

10. Market Barriers

11. Appendix

11.1. Report Methodology

12. DelveInsight Capabilities

13. Disclaimer

14. About DelveInsight

Table 1: Genes associated with BPD

Table 2: Total Cases of Bronchopulmonary Dysplasia (BPD) in 7MM (2017-2028)

Table 3: Preterm and Early Preterm Cases in the US (2017-2028)

Table 4: Total Cases of BPD in the US (2017-2028)

Table 5: Total Cases of Bronchopulmonary Dysplasia based on Severity in the US (2017-2028)

Table 6: Preterm and Early Preterm Cases in Germany (2017-2028)

Table 7: Total Cases of BPD in Germany (2017-2028)

Table 8: Total Cases of Bronchopulmonary Dysplasia based on Severity in Germany (2017-2028)

Table 9: Preterm and Early Preterm Cases in France (2017-2028)

Table 10: Total Cases of BPD in France (2017-2028)

Table 11: Total Cases of Bronchopulmonary Dysplasia based on Severity in France (2017-2028)

Table 12: Preterm and Early Preterm Cases in Italy (2017-2028)

Table 13: Total Cases of BPD in Italy (2017-2028)

Table 14: Total Cases of Bronchopulmonary Dysplasia based on Severity in Italy (2017-2028)

Table 15: Preterm and Early Preterm Cases in Spain (2017-2028)

Table 16: Total Cases of BPD in Spain (2017-2028)

Table 17: Total Cases of Bronchopulmonary Dysplasia based on Severity in Spain (2017-2028)

Table 18: Preterm and Early Preterm Cases in the UK (2017-2028)

Table 19: Total Cases of BPD in the UK (2017-2028)

Table 20: Total Cases of Bronchopulmonary Dysplasia based on Severity in the UK (2017-2028)

Table 21: Preterm and Early Preterm Cases in Japan (2017-2028)

Table 22: Total Cases of BPD in Japan (2017-2028)

Table 23: Total Cases of Bronchopulmonary Dysplasia based on Severity in Japan (2017-2028)

Table 24: Factors that may decrease or increase the GRADE quality of evidence

Table 25: Summary of the overall level of evidence and recommendations for therapies to prevent BPD in infants born less than 32 weeks' gestation

Table 26: Levels of evidence and recommendations for clinical use based on the guidelines developed by the US preventive services task force

Table 27: Management of BPD According to Phase (Early, Evolving, and Established)

Table 28: Key Cross of emerging Therapies

Table 29: PNEUMOSTEM, Clinical Trial Description, 2019

Table 30: AEROSURF, Clinical Trial Description 2019

Table 31: CG100, Clinical Trial Description 2019

Table 32: SHP607, Clinical Trial Description 2019

Table 33: Market Size of Bronchopulmonary Dysplasia in 7MM in USD Million (2017-2028)

Table 34: Market Size of BPD by therapies in 7MM in USD Million (2017-2028)

Table 35: The US Market Size of Bronchopulmonary Dysplasia (BPD) in USD Million (2017-2028)

Table 36: Market Size of BPD by therapies in the US in USD Million (2017-2028)

Table 37: Germany Market Size of Bronchopulmonary Dysplasia in USD Million (2017-2028)

Table 38: Market Size of BPD by therapies in Germany in USD Million (2017-2028)

Table 39: France Market Size of Bronchopulmonary Dysplasia in USD Million (2017-2028)

Table 40: Market Size of BPD by therapies in France in USD Million (2017-2028)

Table 41: Italy Market Size of Bronchopulmonary Dysplasia in USD Million (2017-2028)

Table 42: Market Size of BPD by therapies in Italy in USD Million (2017-2028)

Table 43: Spain Market Size of Bronchopulmonary Dysplasia in USD Million (2017-2028)

Table 44: Market Size of BPD by therapies in Spain in USD Million (2017-2028)

Table 45: UK Market Size of Bronchopulmonary Dysplasia in USD Million (2017-2028)

Table 46: Market Size of BPD by therapies in the UK in USD Million (2017-2028)

Table 47: Japan Market Size of Bronchopulmonary Dysplasia in USD Million (2017-2028)

Table 48:Market Size of BPD by therapies in Japan in USD Million (2017-2028)

Figure 1: Signs and Symptoms of BPD

Figure 2: Pathogenesis of BPD : impact of the pulmonary inflammatory response on the premature lung

Figure 3: Total Cases of Bronchopulmonary Dysplasia in 7MM (2017-2028)

Figure 4: Preterm and Early Preterm Cases in the US (2017-2028)

Figure 5: Total Cases of BPD in the US (2017-2028)

Figure 6: Total Cases of Bronchopulmonary Dysplasia based on Severity in the US (2017-2028)

Figure 7: Preterm and Early Preterm Cases in Germany (2017-2028)

Figure 8: Total Cases of BPD in Germany (2017-2028)

Figure 9: Total Cases of Bronchopulmonary Dysplasia based on Severity in Germany (2017-2028)

Figure 10: Preterm and Early Preterm Cases in France (2017-2028)

Figure 11: Total Cases of BPD in France (2017-2028)

Figure 12: Total Cases of Bronchopulmonary Dysplasia based on Severity in France (2017-2028)

Figure 13: Preterm and Early Preterm Cases in Italy (2017-2028)

Figure 14: Total Cases of BPD in Italy (2017-2028)

Figure 15: Total Cases of Bronchopulmonary Dysplasia based on Severity in Italy (2017-2028)

Figure 16: Preterm and Early Preterm Cases in Spain (2017-2028)

Figure 17: Total Cases of BPD in Spain (2017-2028)

Figure 18: Total Cases of Bronchopulmonary Dysplasia based on Severity in Spain (2017-2028)

Figure 19: Preterm and Early Preterm Cases in the UK (2017-2028)

Figure 20: Total Cases of BPD in the UK (2017-2028)

Figure 21: Total Cases of Bronchopulmonary Dysplasia based on Severity in the UK (2017-2028)

Figure 22: Preterm and Early Preterm Cases in Japan (2017-2028)

Figure 23: Total Cases of BPD in Japan (2017-2028)

Figure 24: Total Cases of Bronchopulmonary Dysplasia based on Severity in Japan (2017-2028)

Figure 25: Algorithm for BPD

Figure 26: Potential non-ventilator-dependent strategies to prevent or ameliorate BPD

Figure 27: Unmet Needs of Bronchopulmonary Dysplasia (BPD)

Figure 28: Market Size of Bronchopulmonary Dysplasia in 7MM in USD Million (2017-2028)

Figure 29: Market Size of BPD by Therapies in 7MM in USD Million (2017-2028)

Figure 30: Market Size of Bronchopulmonary Dysplasia in the US, USD Millions (2017-2028)

Figure 31: Market Size of BPD by therapies in the US in USD Million (2017-2028)

Figure 32: Market Size of Bronchopulmonary Dysplasia in Germany, USD Millions (2017-2028)

Figure 33: Market Size of BPD by therapies in Germany in USD Million (2017-2028)

Figure 34: Market Size of Bronchopulmonary Dysplasia in France, USD Millions (2017-2028)

Figure 35: Market Size of BPD by therapies in France in USD Million (2017-2028)

Figure 36: Market Size of Bronchopulmonary Dysplasia in Italy, USD Millions (2017-2028)

Figure 37: Market Size of BPD by therapies in Italy in USD Million (2017-2028)

Figure 38: Market Size of Bronchopulmonary Dysplasia in Spain, USD Millions (2017-2028)

Figure 39: Market Size of BPD by therapies in Spain in USD Million (2017-2028)

Figure 40: Market Size of Bronchopulmonary Dysplasia in the UK, USD Millions (2017-2028)

Figure 41: Market Size of BPD by therapies in the UK in USD Million (2017-2028)

Figure 42: Market Size of Bronchopulmonary Dysplasia in Japan, USD Millions (2017-2028)

Figure 43: Market Size of BPD by therapies in Japan in USD Million (2017-2028)

Figure 44: Market Drivers

Figure 45:Market Barriers

  • Tags:
  • Bronchopulmonary Dysplasia (BPD) ma...
  • Bronchopulmonary Dysplasia (BPD) ma...
  • Bronchopulmonary Dysplasia (BPD) ma...
  • Bronchopulmonary Dysplasia (BPD) ma...
  • Bronchopulmonary Dysplasia (BPD) ma...
  • Bronchopulmonary Dysplasia (BPD) ma...
  • Bronchopulmonary Dysplasia (BPD) pi...
  • Bronchopulmonary Dysplasia (BPD) tr...
  • Bronchopulmonary Dysplasia (BPD) dr...
  • Bronchopulmonary Dysplasia (BPD) sa...
  • Bronchopulmonary Dysplasia (BPD) ma...
  • Bronchopulmonary Dysplasia (BPD) di...
  • Bronchopulmonary Dysplasia (BPD) ep...
  • Bronchopulmonary Dysplasia (BPD)
  • Bronchopulmonary Dysplasia (BPD) Co...
  • Bronchopulmonary Dysplasia (BPD) P...

Forward to Friend

Need A Quote